As the human body's largest organ, it's no surprise that an endless number of things can go wrong with your skin.There are the lumps and bumps that can appear out of nowhere.

Was that mole always there? Photograph, track, and identify marks with these apps before you head to your dermatologist.

Cutaneous squamous cell carcinoma (CSCC) is a type of cancer that develops in squamous skin cells and is typically caused by exposure to ultraviolet (UV) radiation.

The best way to know is to monitor your skin regularly and look for changes. Any new growth, sore that doesn’t heal, or a change in a mole could be a warning sign. The ABCDEs of melanoma — Asymmetry, ...

Prognosis: Removal typically cures the cancer. Most SCCs are slow-growing, though this type of skin cancer is more likely to grow deeper into the skin and spread. If SCCs spread to other organs, ...

People with locally advanced head and neck squamous cell carcinoma (HNSCC) now have a new treatment option that could extend their lives with fewer side effects. The U.S. Food and Drug Administration ...

CHANCES ARE, ONE out of five of you reading this will be diagnosed with skin cancer by the time you hit age 70. As the most ...

Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines ...

Shlomo Koyfman, MD, discusses the MK-3475-630/ KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer. Shlomo Koyfman, MD, a radiation oncologist at Cleveland ...

Libtayo (cemiplimab), approved as treatment for advanced cases of squamous cell carcinoma of the skin, might soon have a role in the treatment of local cases of the disease. Results of a phase 3 trial ...

The nectin-4–targeted antibody-drug conjugate (ADC) ADRX-0706 has received FDA fast track designation for use in patients with locally advanced or metastatic squamous cell cervical cancer. 1 The agent ...

In patients with up to 63% central squamous carcinoma, ivonescimab demonstrated a safety profile comparable to the control group. This highlights its potential to overcome the limitations of ...